Epoetin kappa - JCR Pharmaceuticals

Drug Profile

Epoetin kappa - JCR Pharmaceuticals

Alternative Names: Epoetin alfa biosimilar - JCR Pharmaceuticals/Kissei Pharmaceuticals; Epoetin alfa biosimilar 1; Epoetin Alfa BS Injection [JCR]; Epoetin Alpha BS Inj. JCR; JR-013

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JCR Pharmaceuticals
  • Developer JCR Pharmaceuticals; Kissei Pharmaceutical
  • Class Antianaemics; Haematopoietic cell growth factors; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 27 May 2010 Launched for Anaemia (in neonates) in Japan (SC) - first global launch
  • 27 May 2010 Launched for Anaemia (renal anaemia in patients undergoing dialysis) in Japan (IV) - first global launch
  • 20 Jan 2010 Registered for Anaemia (in neonates) in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top